Clinical Trial Detail

NCT ID NCT03922477
Title A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

acute myeloid leukemia

Therapies

Atezolizumab + Hu5F9-G4

Age Groups: senior adult

No variant requirements are available.